258 related articles for article (PubMed ID: 8504511)
1. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.
Ridker PM; Gaboury CL; Conlin PR; Seely EW; Williams GH; Vaughan DE
Circulation; 1993 Jun; 87(6):1969-73. PubMed ID: 8504511
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells.
van Leeuwen RT; Kol A; Andreotti F; Kluft C; Maseri A; Sperti G
Circulation; 1994 Jul; 90(1):362-8. PubMed ID: 8026020
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
Vaughan DE; Lazos SA; Tong K
J Clin Invest; 1995 Mar; 95(3):995-1001. PubMed ID: 7884001
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.
Nakamura S; Nakamura I; Ma L; Vaughan DE; Fogo AB
Kidney Int; 2000 Jul; 58(1):251-9. PubMed ID: 10886570
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.
Labinjoh C; Newby DE; Dawson P; Johnston NR; Ludlam CA; Boon NA; Webb DJ
Cardiovasc Res; 2000 Sep; 47(4):707-14. PubMed ID: 10974219
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
[TBL] [Abstract][Full Text] [Related]
7. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
[TBL] [Abstract][Full Text] [Related]
8. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
Brown NJ; Agirbasli MA; Williams GH; Litchfield WR; Vaughan DE
Hypertension; 1998 Dec; 32(6):965-71. PubMed ID: 9856958
[TBL] [Abstract][Full Text] [Related]
9. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
10. Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects.
Lottermoser K; Hertfelder HJ; Gohlke P; Vetter H; Düsing R
Clin Exp Hypertens; 2004 Jan; 26(1):13-26. PubMed ID: 15000294
[TBL] [Abstract][Full Text] [Related]
11. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension.
Sakata K; Pawlak R; Urano T; Takada A
Pathophysiol Haemost Thromb; 2002; 32(2):67-75. PubMed ID: 12214151
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo.
Ekholm M; Kahan T; Jörneskog G; Bröijersen A; Wallén NH
Thromb Res; 2009 May; 124(1):110-5. PubMed ID: 19195683
[TBL] [Abstract][Full Text] [Related]
13. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
[TBL] [Abstract][Full Text] [Related]
14. L-158,809 and (D-Ala(7))-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells.
Yoshida M; Naito Y; Urano T; Takada A; Takada Y
Thromb Res; 2002 Mar; 105(6):531-6. PubMed ID: 12091055
[TBL] [Abstract][Full Text] [Related]
15. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
16. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Pedersen OD; Gram J; Jeunemaitre X; Billaud E; Jespersen J
Coron Artery Dis; 1997 May; 8(5):283-91. PubMed ID: 9285181
[TBL] [Abstract][Full Text] [Related]
17. Effect of angiotensin peptides on PAI-1 expression and production in human adipocytes.
Skurk T; Lee YM; Röhrig K; Hauner H
Horm Metab Res; 2001 Apr; 33(4):196-200. PubMed ID: 11383921
[TBL] [Abstract][Full Text] [Related]
18. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic function in diuretic-induced volume depletion.
Lottermoser K; Hertfelder HJ; Vetter H; Düsing R
Am J Hypertens; 2000 Apr; 13(4 Pt 1):359-63. PubMed ID: 10821336
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin and vascular fibrinolytic balance.
Vaughan DE
Am J Hypertens; 2002 Jan; 15(1 Pt 2):3S-8S. PubMed ID: 11824873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
